A case of adult attention-deficit/hyperactivity disorder alleviated by milnacipran

@article{Kako2007ACO,
  title={A case of adult attention-deficit/hyperactivity disorder alleviated by milnacipran},
  author={Yuki Kako and Yusuke Niwa and Atsuhito Toyomaki and Hiroyoshi Yamanaka and Nobuki Kitagawa and Kenzo Denda and Tsukasa Koyama},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  year={2007},
  volume={31},
  pages={772-775}
}
  • Yuki Kako, Y. Niwa, T. Koyama
  • Published 13 April 2007
  • Psychology, Biology
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry
Milnacipran for Attention-Deficit Hyperactivity Disorder Symptoms in Adult Asperger’s Disorder
TLDR
Milnacipran might be useful for ADHD symptoms, exerting its effects by increasing serotonin and noradrenaline activities in Asperger’s disorder.
Recurrent Suicidal Ideation During Intravenous Ketamine Treatment.
TLDR
This case represents one of the earliest reports on the safety and efficacy of milnacipran in CAP population as an add-on treatment for difficult-to-treat cases of ADHD with comorbid anxiety and enuresis and well-conducted large studies are needed to replicate this finding.
Add-on Milnacipran Boosts Methylphenidate Response in an Adolescent With Attention-Deficit/Hyperactivity Disorder With Comorbid Anxiety and Enuresis.
TLDR
DFX-G was associated with greater satisfaction and clinically sufficient ferritin control compared with the findings for DFX-DT, and no patients required dose reduction because of safety issues, however, physicians will need to monitor the DFX dose after switching the formula.
The effects of serotonin and/or noradrenaline reuptake inhibitors on impulsive-like action assessed by the three-choice serial reaction time task: a simple and valid model of impulsive action using rats
TLDR
The results indicate that the 3-CSRTT could provide an appropriate and simpler rodent model of impulsive-like action and that milnacipran could have some beneficial effects on impulsivity-related disorders.
Effects of norepinephrine transporter gene variants on NET binding in ADHD and healthy controls investigated by PET
TLDR
The role of genetic influence of the NE system on NET binding to be pertubated in ADHD is supported, and symptoms of hyperactivity and impulsivity correlated with NET BPND in the cerebellum depending on genotype.
Molecular Imaging in Adult Attention Deficit / Hyperactivity Disorder
Molecular Imaging in Adult Attention Deficit/Hyperactivity Disorder (ADHD) ....... v ABSTRACT (Deutsch) Molekulare Bildgebung in der AufmerksamkeitsdefizitundDeutsch) Molekulare Bildgebung in der
Pharmacological fMRI on the effects of Fluoxetine on functions of working memory, impulsiveness and cognitive flexibility in boys with Attention Deficit Hyperactivity Disorder and boys with Autism Spectrum Disorder
Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence.

References

SHOWING 1-10 OF 28 REFERENCES
An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder.
TLDR
Data suggest that controlled trials should be conducted with venlafaxine for ADHD, and patients who could tolerate the medication and showed a good response that was well maintained are suggested.
Open-label trial of venlafaxine in adults with attention deficit disorder.
TLDR
The results of an open-label trial of the recently marketed antidepressant venlafaxine in 16 adult patients with ADD decreased ADD ratings by almost half.
Attention-deficit hyperactivity disorder in adults.
  • P. Wender
  • Psychology
    The Psychiatric clinics of North America
  • 1998
Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder.
TLDR
Adderall was effective and well tolerated in the short-term treatment of adults with ADHD and more work is needed to evaluate the long-term effects of Adderall, or other amphetamine compounds, in the treatment of adult attention-deficit/hyperactivity disorder.
Neurobiology of attention deficit disorder with hyperactivity: where have we come in 50 years?
  • A. Zametkin, J. Rapoport
  • Psychology, Medicine
    Journal of the American Academy of Child and Adolescent Psychiatry
  • 1987
TLDR
The most promising areas for research at this time appear to be in-depth studies of response to stimulants and more physiological studies using brain imaging techniques.
Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder.
TLDR
This preliminary study showed that tomoxetine was effective in treating adult ADHD and was well tolerated, and these promising results provide support for further studies of tomoxettine over an extended period of treatment.
Attention-deficit/hyperactivity disorder: a life-span perspective.
  • J. Biederman
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 1998
TLDR
A variety of pharmacologic agents are available in treating ADHD: stimulant medications remain the first-line treatment for noncomorbid ADHD, whereas tricyclic antidepressants and bupropion are recommended for stimulant nonresponders and patients with more than one psychiatric disorder.
Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial.
TLDR
Venlafaxine may be a promising agent for the treatment of ADHD in adults and controlled clinical trials are needed to further examine this issue.
Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder.
TLDR
The absence of cognitive deterioration from atomoxetine, along with improved performance in a subgroup of patients in this large study, supports the safety of atomxetine in this regard and its potential for improving a significant source of impairment for adults with ADHD.
A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults.
TLDR
The results suggest a therapeutic role for bupropion in the armamentarium of agents for ADHD in adults, while further validating the continuity of pharmacological responsivity of ADHD across the lifespan.
...
...